Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma

NCT00985907 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT00985907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00985907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Lead sponsor
University of California, San Francisco
Phase
Phase 1/2
Overall status
Terminated
Start date
October 28, 2004
Completion date
January 12, 2010
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, patient participation